Effect of SARS-CoV-2 coinfection was not apparent on the dynamics of chronic hepatitis B infection

Yu, Rentao; Tan, Shengkui; Dan, Yunjie; Lu, Yanqiu; Zhang, Juan; Tan, Zhuo; He, Xiaoqing; Xiang, Xiaomei; Zhou, Yi; Guo, Yanzhi; Deng, Guohong; Chen, Yaokai; Tan, Wenting

doi:10.1016/j.virol.2020.11.012

Cited by 19 publications

(19 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the third step, the full text of the 372 remained articles was comprehensively studied, and we exclude the 308 studies. A total of 64 studies 3,5,18,23–79 with 61,547 total sample size were included in our study. Selection process flow chart is available in Figure 1, and Table 1 shows the studies’ characteristics.…”

Section: Resultsmentioning

confidence: 99%

“…In the third step, the full text of the 372 remained articles was comprehensively studied, and we exclude the 308 studies. A total of 64 studies 3 , 5 , 18 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 ...…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Worldwide prevalence of microbial agents’ coinfection among COVID‐19 patients: A comprehensive updated systematic review and meta‐analysis

Pakzad

Malekifar

Shateri

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background To provide information about pathogens’ coinfection prevalence with SARS‐CoV‐2 could be a real help to save patients’ lives. This study aims to evaluate the pathogens’ coinfection prevalence among COVID‐19 patients. Method In order to find all of the relevant articles, we used systematic search approach. Research‐based databases including PubMed, Web of Science, Embase, and Scopus, without language restrictions, were searched to identify the relevant bacterial, fungal, and viral coinfections among COVID‐19 cases from December 1, 2019, to August 23, 2021. In order to dig deeper, other scientific repositories such as Medrxiv were probed. Results A total of 13,023 studies were found through systematic search. After thorough analysis, only 64 studies with 61,547 patients were included in the study. The most common causative agents of coinfection among COVID‐19 patients were bacteria (pooled prevalence: 20.97%; 95% CI: 15.95–26.46; I2: 99.9%) and less frequent were virus coinfections (pooled prevalence: 12.58%; 95% CI: 7.31–18.96; I2: 98.7%). The pooled prevalence of fungal coinfections was also 12.60% (95% CI: 7.84–17.36; I2: 98.3%). Meta‐regression analysis showed that the age sample size and WHO geographic region did not influenced heterogeneity. Conclusion We identified a high prevalence of pathogenic microorganism coinfection among COVID‐19 patients. Because of this rate of coinfection empirical use of antibacterial, antifungal, and antiviral treatment are advisable specifically at the early stage of COVID‐19 infection. We also suggest running simultaneously diagnostic tests to identify other microbiological agents’ coinfection with SARS‐CoV‐2.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Worldwide prevalence of microbial agents’ coinfection among COVID‐19 patients: A comprehensive updated systematic review and meta‐analysis

Pakzad

Malekifar

Shateri

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…The use of IFNα inhalation was reported in patients with various comorbidities and conditions, including patients with atopic dermatitis, [38] allergic rhinitis, [38] bronchiolitis, [25] chronic obstructive pulmonary disease, [84] , [162] tuberculosis, [55] cardiovascular disease, [22] hypertension, [22] , [84] , [150] , [162] diabetes, [32] , [39] hyperlipidemia, [150] obesity, [126] metabolic syndrome, [192] chronic hepatitis B infection, [76] , [153] chronic kidney disease, [22] , [70] malignancy, [163] liver transplant, [50] kidney transplant, [70] , [172] and pregnancy. [19] The use of subcutaneous injection of IFNα was reported in patients with diabetes, [42] hypertension, [42] , [44] hyperlipidemia, 42 chronic hepatitis B infection, [140] primary myelofibrosis with macrocytic anemia, [44] dementia, [44] chronic kidney disease, [44] Behcet's disease, [190] and osteoporosis.…”

Section: Comprehensive Review Of the Literature On The Safety And Efficacy Of Interferon Alpha Treatment In Covid-19 Patientsmentioning

confidence: 99%

Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review

Lu¹,

Feng²,

Yu³

et al. 2022

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Recent studies have identified an association between perturbed type I interferon (IFN) responses and the severity of coronavirus disease 2019 (COVID-19). IFNα intervention may normalize the dysregulated innate immunity of COVID-19. However, details regarding its utilization and therapeutic evidence have yet to be systematically evaluated. The aim of this comprehensive review was to summarize the current utilization of IFNα for COVID-19 treatment and to explore the evidence on safety and efficacy. A comprehensive review of clinical studies in the literature prior to December 1 st , 2021, was performed to identify the current utilization of IFNα, which included details on the route of administration, the number of patients who received the treatment, the severity at the initiation of treatment, age range, the time from the onset of symptoms to treatment, dose, frequency, and duration as well as safety and efficacy. Encouragingly, no evidence was found against the safety of IFNα treatment for COVID-19. Early intervention, either within five days from the onset of symptoms or at hospital admission, confers better clinical outcomes, whereas late intervention may result in prolonged hospitalization.

show abstract

“…During the acute course of SARS-CoV-2 infection, markers of HBV replication did not substantially fluctuate. Furthermore, the co-infection of HBV did not extend the viral shedding cycle or incubation periods of SARS-CoV-2; hence, they concluded that the effects of SARS-CoV-2 on the dynamics of chronic HBV infection were not visible and hence could not be related to the source of HBV reactivation, at least in the seven patients with chronic HBV that they studied [ 108 ]. However, the number of HBsAg-positive patients was too low to address this issue with any conviction.…”

Section: Hepatic Derangements Viral Hepatitis and Covid-19mentioning

confidence: 99%

Infection of Human Cells by SARS-CoV-2 and Molecular Overview of Gastrointestinal, Neurological, and Hepatic Problems in COVID-19 Patients

Rahban

Stanek

Hooshmand

et al. 2021

JCM

View full text Add to dashboard Cite

The gastrointestinal tract is the body’s largest interface between the host and the external environment. People infected with SARS-CoV-2 are at higher risk of microbiome alterations and severe diseases. Recent evidence has suggested that the pathophysiological and molecular mechanisms associated with gastrointestinal complicity in SARS-CoV-2 infection could be explained by the role of angiotensin-converting enzyme-2 (ACE2) cell receptors. These receptors are overexpressed in the gut lining, leading to a high intestinal permeability to foreign pathogens. It is believed that SARS-CoV-2 has a lesser likelihood of causing liver infection because of the diminished expression of ACE2 in liver cells. Interestingly, an interconnection between the lungs, brain, and gastrointestinal tract during severe COVID-19 has been mentioned. We hope that this review on the molecular mechanisms related to the gastrointestinal disorders as well as neurological and hepatic manifestations experienced by COVID-19 patients will help scientists to find a convenient solution for this and other pandemic events.

show abstract

Effect of SARS-CoV-2 coinfection was not apparent on the dynamics of chronic hepatitis B infection

Cited by 19 publications

References 14 publications

Worldwide prevalence of microbial agents’ coinfection among COVID‐19 patients: A comprehensive updated systematic review and meta‐analysis

Worldwide prevalence of microbial agents’ coinfection among COVID‐19 patients: A comprehensive updated systematic review and meta‐analysis

Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review

Infection of Human Cells by SARS-CoV-2 and Molecular Overview of Gastrointestinal, Neurological, and Hepatic Problems in COVID-19 Patients

Contact Info

Product

Resources

About